BioVaxys Technology Corp.
BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.
BioVaxys Technology Corp. (BIOV)
BioVaxys Technology Corp. (BIOV)
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| National Bank Financial Inc. | 9,000 | 0.045 | 0.05 | 22,000 | BMO Nesbitt Burns Inc. |
| CIBC World Markets Inc. | 50,000 | 0.045 | 0.05 | 1,000 | TD Securities Inc. |
| National Bank Financial Inc. | 1,000 | 0.045 | 0.05 | 50,000 | BMO Nesbitt Burns Inc. |
| Questrade Inc. | 70,000 | 0.04 | 0.05 | 160,000 | RBC Capital Markets |
| CIBC World Markets Inc. | 50,000 | 0.04 | 0.05 | 1,000 | TD Securities Inc. |
| CIBC World Markets Inc. | 50,000 | 0.04 | 0.05 | 1,000 | TD Securities Inc. |
| CIBC World Markets Inc. | 100,000 | 0.04 | 0.05 | 1,000 | National Bank Financial Inc. |
| W.D. Latimer Co. Limited | 15,000 | 0.04 | 0.05 | 18,000 | CIBC World Markets Inc. |
| TD Securities Inc. | 1,000 | 0.04 | 0.055 | 21,000 | CIBC World Markets Inc. |
| CIBC World Markets Inc. | 10,000 | 0.04 | 0.055 | 127,000 | RBC Capital Markets |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| 0 | 0.00 | 0.05 | 9,000 | Anonymous | |
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 3 | 60,000 | 0.045 | 0.05 | 254,000 | 8 |
| 16 | 425,000 | 0.04 | 0.055 | 347,000 | 11 |
| 7 | 201,000 | 0.035 | 0.06 | 46,000 | 7 |
| 5 | 183,000 | 0.03 | 0.065 | 104,000 | 15 |
| 4 | 129,000 | 0.025 | 0.07 | 100,000 | 3 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 0 | 0 | 0.00 | 0.05 | 9,000 | 1 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Apr 7, 19:59 | 0.05 | 0.00 | 1,000 | Questrade Inc. | Anonymous | CSE2 |
| Apr 7, 19:57 | 0.045 | -0.005 | 2,000 | National Bank Financial Inc. | TD Securities Inc. | CSE |
| Apr 7, 19:57 | 0.045 | -0.005 | 10,000 | Anonymous | TD Securities Inc. | CSE |
| Apr 7, 19:57 | 0.045 | -0.005 | 3,000 | National Bank Financial Inc. | TD Securities Inc. | CSE |
| Apr 7, 19:57 | 0.045 | -0.005 | 5,000 | National Bank Financial Inc. | TD Securities Inc. | CSE |
Company Info
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Bulletins
2024-0715 - Reinstatement - BioVaxys Technology Corp. (BIOV)
le 16 juillet/July 2024
Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.
The Company has rectified the situation that gave rise to the suspension.
____________________________
Avec effet immédiat, BioVaxys Technology Corp. sera réintégrée à la négociation.
La Société a rectifié la situation qui a donné lieu à la suspension.
CSE Filings
